Introduction:

Acute interstitial nephritis (AIN) can occur as a component of tubulointerstitial nephritis with uveitis (TINU) syndrome, a rare autoimmune disorder characterized by simultaneous renal and ocular inflammation. This article explores the unique features of AIN in TINU syndrome, including its pathogenesis, clinical manifestations, diagnosis, and treatment strategies.

Pathogenesis:

• Immune Dysregulation: TINU syndrome is believed to result from dysregulated immune responses, leading to the infiltration of inflammatory cells in the renal interstitium and uveal tissues.
• T-Cell Activation: Activation of T lymphocytes triggers the release of pro-inflammatory cytokines, chemokines, and cytotoxic mediators, contributing to tubulointerstitial inflammation and renal injury in TINU syndrome.
• Autoimmune Mechanisms: Autoantibodies targeting renal and ocular antigens may play a role in the pathogenesis of TINU syndrome, though specific autoantibodies have not been consistently identified.

Clinical Manifestations:

Renal Involvement:

• AIN: The hallmark renal manifestation of TINU syndrome is AIN, characterized by interstitial inflammation, tubular injury, and acute kidney injury (AKI).
• Clinical Features: Patients may present with nonspecific symptoms such as fatigue, malaise, fever, and flank pain, alongside laboratory abnormalities including elevated serum creatinine and eosinophilia.

Ocular Manifestations:

• Uveitis: Uveitis, typically anterior or bilateral, is the predominant ocular manifestation of TINU syndrome, presenting with symptoms such as eye pain, photophobia, redness, and visual disturbances.

Diagnosis:

Clinical Evaluation:

• Comprehensive Assessment: A thorough history and physical examination, including evaluation of renal and ocular symptoms, aid in suspecting TINU syndrome.
• Laboratory Tests: Blood tests may reveal elevated inflammatory markers, eosinophilia, and abnormal renal function tests (e.g., elevated serum creatinine, proteinuria).

Ophthalmologic Evaluation:

• Slit-Lamp Examination: Ophthalmologic examination, including slit-lamp examination, helps identify characteristic signs of uveitis such as anterior chamber inflammation, keratic precipitates, and vitreous haze.

Renal Biopsy:

• Histopathological Findings: Renal biopsy may demonstrate interstitial edema, lymphocytic infiltration, tubulitis, and eosinophilic infiltrates, confirming the diagnosis of AIN in TINU syndrome.

Treatment Strategies:

Corticosteroids:

• First-Line Therapy: Systemic corticosteroids, such as prednisone or methylprednisolone, are the mainstay of treatment for TINU syndrome-associated AIN and uveitis.
• Dosage and Duration: High-dose corticosteroid therapy followed by gradual tapering over several weeks to months is typically employed, guided by clinical response and disease activity.

Immunosuppressive Agents:

• Adjunctive Therapy: In cases of severe or refractory disease, adjunctive immunosuppressive agents such as methotrexate, mycophenolate mofetil, or azathioprine may be considered to achieve disease remission and minimize corticosteroid-related adverse effects.

Ophthalmologic Treatment:

• Topical Steroids: Topical corticosteroids, cycloplegic agents, and nonsteroidal anti-inflammatory drugs (NSAIDs) may be used to manage ocular inflammation and prevent complications of uveitis.

Prognosis:

Renal Outcome:

• Variable Prognosis: The prognosis of AIN in TINU syndrome varies widely, with most patients experiencing complete renal recovery with prompt diagnosis and appropriate treatment.
• Chronic Kidney Disease: In rare cases, chronic tubulointerstitial fibrosis and irreversible renal damage may ensue, necessitating long-term monitoring for the progression of chronic kidney disease (CKD).

Ocular Outcome:

• Favorable Prognosis: Uveitis in TINU syndrome generally responds well to corticosteroid therapy, with a low risk of ocular complications such as cataracts, glaucoma, and retinal damage.

Conclusion:

AIN in the context of TINU syndrome represents a unique clinical entity characterized by simultaneous renal and ocular inflammation. Timely recognition, prompt treatment with corticosteroids and immunosuppressive agents, and multidisciplinary management involving nephrologists and ophthalmologists are essential for optimizing outcomes in patients with TINU syndrome-associated AIN.

Hashtags: #TINUSyndrome #AcuteInterstitialNephritis #RenalOcularInflammation #TreatmentStrategies